Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2/3 treatment-option protocol of brentuximab vedotin for placebo-arm patients from SGN35-005
2010-020363-21Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jul 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Seagen Inc. Primary endpoint: Safety profile of brentuximab vedotin in crossover population. Started Jul 2010; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2010-020363-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020363-21.